Nurix Therapeutics Inc
NASDAQ:NRIX
Nurix Therapeutics Inc
NASDAQ:NRIX
Price:
15.9 USD
6.35%
Market Closed
Updated:
May 16, 2024
Section:
Relative Value
The Relative Value of one
NRIX
stock under the Base Case scenario is
29.42
USD.
Compared to the current market price of 15.9 USD,
Nurix Therapeutics Inc
is
Undervalued by 46%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NRIX
Relative Value
Base Case
29.42
USD
Undervaluation 46%
Valuation Multiples
Multiples Across Competitors
NRIX Competitors Multiples
Nurix Therapeutics Inc Competitors
Nurix Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
873m USD | 10.8 | -6 | -4.2 | -4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.1B USD | 5.3 | 60 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 5.8 | 45.5 | 19.1 | 31.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 11.4 | 31.1 | 25.2 | 26.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 8.2 | 27.9 | 22.6 | 25.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
136.7B AUD | 6.5 | 37.1 | 22.4 | 27.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.7B USD | 3 | 172.9 | 7 | 9.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.3B USD | 9.6 | -8.3 | -9.1 | -8.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
34.2B USD | 3.5 | 29.3 | 14.9 | 18.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
